Article

Adapt AO outperforms conventional lens

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL.

At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL, according to Ann Haustermans, Belgium.

The multicentre, prospective, intra-individual, comparative study enrolled 69 patients requiring bilateral cataract surgery. One eye of each subject received the Adapt AO and the other the spherical Akreos Adapt lens. Follow-up data was collected at one and three months and one and two years, and patients completed a questionnaire assessing their quality of vision at three months.

At one-month follow-up, the Adapt AO performed significantly better in low contrast UCVA (p=0.03) and BCVA (p=0.047). It was also found to perform better than the spherical Adapt at all spatial frequencies in photopic contrast sensitivity and at 1, 5 and 6 cpd in mesopic contrast sensitivity. At three-months follow-up, the lenses performed equally but at one year the Adapt AO performed better in high contrast UCVA and BCVA.

Dr Haustermanns concluded that the aspheric Akreos Adapt AO lens offers better optical performance than the conventional spherical Adapt IOL.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.